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Abstract: This review summarises molecular pathological techniques applicable to thyroid FNA. The 
molecular pathology of thyroid tumours is now fairly well understood. Molecular methods may be 
used as a rule-in test for diagnosis of malignancy in thyroid nodules e.g. BRAF V600E point mutation, 
use of a 7 gene mutational panel (BRAF V600E, RAS genes, RET/PTC or PAX8/PPARG rearrangement), 
or as a comprehensive multigene next-generation sequencing panel e.g. ThyroSeq v2.  Molecular 
methods can also be applied as rule-out tests for malignancy in thyroid nodules e.g. Afirma or 
ThyroSeq v2 or as markers of prognosis e.g. TERT promoter mutation or other gene mutations 
including BRAF V600E, TP53 & AKT1 and as tests for newly defined tumour entities such as NIFTP, or 
as a molecular marker(s) for targeted therapies. This review describes practical examples of 
molecular techniques as applied to thyroid FNA in routine clinical practice. 
  
3 
 
Introduction 
There have been major advances in molecular pathological techniques in the last few years, 
particularly with the introduction of next-generation sequencing for DNA and RNA. [1] Knowledge of 
the pathology of thyroid tumours has also evolved. Molecular diagnosis for thyroid nodules can be 
used for differential diagnosis of a thyroid nodule, patient prognostication, and as a molecular 
marker for targeted therapy. This review will concentrate on the use of molecular methods for 
diagnosis and prognostication.  The molecular pathology of thyroid tumours is now comparatively 
well understood. [2, 3] Thyroid tumours are thought to arise as a result of multiple mutational 
events. Although thyroid nodules are extremely common most thyroid nodules are benign.  The risk 
of thyroid malignancy in any given thyroid nodule also depends on the patient’s age, genetics, and 
previous history including radiation exposure.  Metastatic tumours to the thyroid gland are also 
important as these are identified in 1.4-3.0% of suspected thyroid cancer patients. [4] 
Papillary Thyroid Carcinoma 
Papillary thyroid carcinoma (PTC) accounts for 85% of thyroid carcinomas; classical type or variants 
of classical type; tall cell, columnar cell, diffuse sclerosing, Warthin-like,  or follicular variant of PTC. 
Classical type PTC shows somatic mutations in the mitogen activated protein kinase (MAPK) 
pathways due to RAS or BRAF mutations, or re-arrangements of RET or NTRK1. Papillary carcinomas 
usually show point mutations, BRAF mutations in 40-45%, RET/PTC rearrangements in 10-20% or RAS 
point mutations in 10-20%. [3] Small PTC tumours localised to the thyroid gland have excellent 
prognosis. Larger PTC tumours or tumours showing extrathyroidal extension or lymphatic or vascular 
invasion have adverse prognosis. Multiple gene mutations in the same tumour, e.g. BRAF V600E and 
TERT promoter, or PIK3CA, AKT1, TP53 mutations in addition to BRAF V600E mutation alone predict 
adverse prognosis. [5-8]. Of interest to cytology is that the aggressive variants of PTC, as well as 
showing cytological and histological differences to classical PTC, also show differing molecular 
profiles.  
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Tall cell variant of PTC shows higher frequency (up to 90% for BRAF V600E) and TERT promoter (31%) 
mutation compared to much lower rates seen in conventional PTC. [9, 10] Columnar cell variant of 
PTC is rare. BRAF V600E mutations are found in one third of these tumours. [11] In hobnail variant 
PTC BRAF V600E mutations are identified in a high percentage of cases, [12] [13] one study showed a 
94.1% rate of BRAF V600E mutation. [14] In diffuse sclerosing variant which is uncommon and 
typically affects younger patients RET/PTC rearrangements are found in a high percentage of cases 
with BRAF V600E mutations rare in the range of 0-61% although most studies suggest zero or very 
low rates of BRAF V600E mutation. [15] ALK translocations are said to be more common in diffuse 
sclerosing variant PTC, seen in one series in 3 of 14 ALK translocated PTC cancer cases although ALK 
fusions did not predict more aggressive tumour behaviour.[16] Solid variant of PTC is a rare variant 
defined by a solid/trabecular growth pattern. Foci of solid variant PTC were identified in papillary 
carcinomas in a small cohort of Chernobyl patients exposed to ionising radiation and were 
associated with RET/PTC3 or ETV6/NTRK3 rearrangements[17]. As the newly described mammary 
analogue secretory carcinoma (MASC) of the thyroid characteristically shows ETV6/NTRK3 fusion it 
has been suggested that some ETV6/NTRK3 fusion solid type PTC might be related to MASC 
tumours.[18] A series of oncocytic variant of PTC showed BRAF V600E mutations in 6 of 15 cases 
(40%).[19] Macrofollicular variant of PTC is extremely rare with less than 80 cases reported.  The 
very few cases studied have shown no evidence of BRAF or RAS mutations.[20] Cribriform-morular 
variant of PTC is an interesting variant, occurring predominantly in young females, either 
sporadically in patients with germline APC mutations or in ~40% of cases it is associated with familial 
adenomatous polyposis. [21]  While the results reported in the literature vary mutations of CTNNB1, 
the gene encoding catenin, or APC mutations are most commonly found, or PIK3CA mutations. 
KRAS mutations, TERT promoter mutation, and RET/PTC mutations are rare and BRAF mutations 
have not been found. Wnt pathway activation is caused by germline APC mutations, or somatic APC 
mutations, and/or somatic CTNNB1 mutations. Aberrant positive nuclear  catenin staining can be 
identified in tumour cells.  
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Follicular Variant of Papillary Thyroid Carcinoma (FVPTC) 
FVPTC typically shows a molecular type similar to that of follicular carcinoma and follicular adenoma 
with RAS mutations, BRAF K601E mutations, and PAX8/PPARGrearrangements which are common in 
follicular carcinomas and rare in classical papillary thyroid carcinoma. [22] 
Follicular Thyroid carcinoma (FTC) 
FTC account for around 10% or less of thyroid carcinomas. BRAF V600E mutations are very unusual 
although BRAF K601E mutations may occur. FTC are similar to that of follicular adenoma with 
mutations of RAS genes in approximately 40-50%, PAX8/PPARG rearrangement in 30-35% of cases, 
PTEN point mutations or small deletions in 5-10% and PIK3CA point mutations in 5-10%.[23] The 
oncocytic (also known as Hurthle cell) subtype of follicular carcinoma shows a much lower frequency 
of RAS point mutations (10-15%) and PAX8/PPARGrearrangements (0-5%) and absence of PIK3CA 
and PTEN point mutations. [24] 
Poorly Differentiated Carcinoma (PDTC) and Anaplastic Carcinoma (ATC) 
PDTC is rare, accounting for less than 1% of thyroid cancers. RAS mutations seen in around 30%, 
BRAF in 15%, TP 53 and catenin in around 25 to 30%. Anaplastic carcinoma typically shows high 
frequency of RAS (20-40%), BRAF V600E (20-40%), TP53 (50-80%) and beta-catenin (5-60%) 
mutations. Anaplastic carcinoma is also characterised by other mutations e.g. PIK3CA, PTEN, AKT1 
and APC mutations, and fusions of ALK and other genes. [25] 
Medullary Thyroid Carcinoma (MTC) 
MTC comprises 2-4% of thyroid malignancies.  Most MTC cases are sporadic although familial cases 
inherited in an autosomal dominant pattern comprise 15 to 30% of cases; MEN 2A, MEN 2B, and 
familial medullary thyroid carcinoma. Medullary carcinoma shows by RET/PTC translocations in more 
than 95% of cases. Familial MTC are associated with gain-of-function mutations in the RET gene. 
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Somatic RET mutations occur in 30-60% of sporadic medullary carcinomas and RAS mutations occur 
in sporadic medullary carcinomas. RAS mutations appear non- overlapping with RET and RAS gene 
mutations. [3] 
NIFTP Tumours 
Circumscribed or encapsulated follicular variant of papillary thyroid carcinoma without capsular or 
vascular invasion which until recently comprised approximately 20% of all newly diagnosed thyroid 
cancers in North America and in some centres elsewhere has now been redesignated as NIFTP, ‘ non-
invasive follicular thyroid neoplasm with papillary like nuclei’. These lesions have very low risk of 
recurrence and are longer designated as carcinomas. [26] NIFTP tumours are RAS driven tumours 
similar to follicular carcinoma and rarely show BRAF V600E mutations (if the very strict diagnostic 
criteria are applied) and frequent presence of RAS mutations, PAX8/PPARG translocations or THADA 
fusions. While some studies show relatively frequent BRAF V600E mutation rates particularly studies 
from Korea, in lesions said to show features of NIFTP, [27] in the authors’ view it is likely that these 
high reported rates of BRAF V600E mutation were achieved because of failure to apply strict 
pathological diagnostic inclusion and exclusion criteria for diagnosis of NIFTP tumours.  NIFTP 
tumours are classified as ‘suspicious’ using Afirma. [28, 29] The use of the revised NIFTP terminology 
is having a major impact on diagnostic thresholds for cytological diagnosis of all categories of thyroid 
FNA. 
Pre-operative Molecular Diagnosis for Thyroid FNA 
Molecular testing can either be used as a ‘rule-in’ or a ‘rule-out’ test for malignancy. [30] The 
performance of the test depends on the positive predictive value (PPV) and the negative predictive 
value (NPV) for malignancy although the PPV and NPV also depend on the pre-test probability of 
malignancy in any given sample.  Individual institutional rates of malignancy vary depending on the 
relevant FNA category. Around 25% of thyroid aspirates are classified as indeterminate; Bethesda 
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category III and IV, in the United Kingdom broadly equivalent to Thy3a and Thy3F and in Italy as 
TIR3a or TIR3f with a published risk of malignancy ranging from 5-30%. [31] 
Approaches to Molecular Diagnosis of Thyroid FNA 
Afirma 
The Afirma Gene Expression Classifer (GEC) (Veracyte, South San Francisco, USA) is a proprietary test 
that uses micro- RNA mRNA profiles for diagnosis of indeterminate nodules. [32] This test is widely 
used in the USA but is not currently routinely commercially available in Europe or elsewhere. Two 
dedicated needle passes are collected into vial of RNA preservative with also FNA passes for routine 
cytology.  This test is most helpful for indeterminate FNA when surgery is not desirable, e.g. small 
nodule size, patient preference, or absence of symptomatic goitre. An initial 25 gene screen for 
expression profiles of less common entities in the thyroid such as metastatic lesions, parathyroid 
tissue, medullary thyroid carcinoma and oncocytic lesions is followed by the main 142 gene 
expression classifier. If one of the six preliminary screening cassettes is triggered the sample is 
reported as a ‘suspicious’. A blinded prospective multicentre trial of 265 nodules with indeterminate 
cytology and histological follow-up was reported in 2012. [32] Centres using Afirma use it as a ‘rule-
out’ test for indeterminate thyroid nodules, that is Bethesda class III and IV nodules. A benign result 
implies a risk of malignancy of around 5-6%, with meta-analysis reporting a pooled sensitivity of 
95.7% and a pooled specificity of 30.5%. [33] A suspicious for malignancy result has the negative 
predictive value of around 85%. The 2012 study showed a low positive predictive value for 
malignancy for indeterminate nodules, 38% for Bethesda category III and 37% for Bethesda category 
IV. The high NPV of a benign GEC result in category IV nodules reduces the risk of malignancy to 
range of 5 to 6% which is comparable to that of a benign aspirate so for category IV FNA a benign 
GEC test result removes the need for surgery. Studies of the GEC show very few carcinomas in the 
few cases that have undergone excision after a benign GEC diagnosis; Nishino in 2016  reported that 
8.5% of benign GEC cases had undergone surgery but only three benign GEC cases were malignant; a 
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6 mm papillary carcinoma, a 32 mm follicular carcinoma and a 28 mm cystic papillary carcinoma.  
[30] Oncocytic FNA’s show a lower risk of malignancy with suspicious GEC results. In 2014 Veracyte 
added the Afirma MTC and Afirma  BRAF, both mRNA classifiers, for identification of the gene 
expression signature for medullary carcinoma [34] and BRAF.[35] 
BRAF V600E Mutation Alone 
BRAF V600E mutation is >99% specific for diagnosis of thyroid cancer. BRAF V600E testing is most 
useful for higher risk FNA’s when nuclear features of papillary carcinoma are suspected but the 
cytological diagnosis remains uncertain, i.e. a diagnosis of Bethesda category IV or V (Thy3F or Thy4) 
where a confident diagnosis of malignancy cannot be made. In these cases companion testing for 
BRAF V600E using a PCR technique will identify BRAF V600E mutations typically in 40-50% of 
Bethesda Category V/Thy4 FNA’s. A meta-analysis of 47 studies of BRAF V600E testing of FNA 
cytology specimens showing a pooled sensitivity for BRAF V600E testing in thyroid FNA of 52% (95% 
CI 39%-64%). Sensitivity when reported in individual studies was 100% but pooled sensitivity for 
indeterminate FNA (category III to V) in the 6 studies where this could be calculated was 31% (95% 
CI, 6%-56%). [36] BRAF V600E testing is also useful because NIFTP tumours, which are follicular 
derived RAS-driven thyroid lesions rarely, if strict diagnostic criteria are applied, show BRAF V600E 
mutations and so the presence of a BRAF V600E mutation can be used to exclude a NIFTP tumour in 
FNA aspirates when nuclear features suggestive of papillary carcinoma are present.  
7 Gene Test 
The so-called ‘7 Gene Test’,  a panel combination of BRAF V600E, PAX8/PPARG, RET/PTC, HRAS, 
KRAS & NRAS [37]has been shown to have greater sensitivity and specificity than BRAF V600E testing 
alone. This approach is one of the methods suggested in The American Thyroid Association 
Statement on Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative 
Decision Making.[38] While this offers more information than BRAF V600E testing alone in practice 
9 
 
the results are often less clear e.g. a study from Europe published in 2017 showed that the 
application of the seven gene panel in a routine primary referral setting did not improve the 
presurgical diagnosis of thyroid FNA. [39] The reasons for this were the presence of RAS gene 
mutations in adenomas as well as malignant tumours and the low frequency of RAS mutation 
positive carcinomas in this study. 
Full Next Generation Sequencing (NGS) Panel : Thyroseq2 
ThyroSeq v2 is both a ‘rule-in’ and ‘rule-out’ test.  The ThyroSeq v2 panel uses NGS for simultaneous 
analysis of multiple genes. ThyroSeq v2 tests for point mutations and small insertions/deletions in 14 
genes, 42 types of gene fusions, and expression levels of 16 genes. Thyroseq 2 detects RET mutations 
(medullary thyroid carcinoma) and also TERT promoter mutation, a mutation, which is both a 
diagnostic and prognostic marker, and present at increased frequency in aggressive tumours such as 
poorly differentiated carcinoma and anaplastic thyroid carcinoma. TERT promoter mutation is 
associated with increased risk of distant metastases, persistent disease, and cancer-specific 
mortality. TP53, PIK3CA, and AKT1 gene mutations are associated with aggressive behaviour and 
tumour progression, particularly when found in combination with early driver events like BRAF or 
RAS mutations. Thyroseq2 detects an extended list of gene fusions including beyond the most 
common RET/PTC1, RET/PTC3, and PAX8-PPARG fusions including additional fusions of RET, BRAF, 
NTRK1 and 3, ALK, and other genes.  Gene expression markers also assess the quality of samples, 
and specifically the proportion of thyroid follicular cells, and also the expression of the calcitonin and 
parathyroid hormone genes, which assists in diagnosis of medullary thyroid carcinoma and 
parathyroid lesions. ThyroSeq v2 was initially validated in a single institutional combined 
retrospective and prospective study of 143 Bethesda Category IV thyroid nodules [40] with a 
specificity of 93%, sensitivity of 90%, PPV of 83% and NPV of 96%. [40] In a follow-up, single 
institution, prospective study of 465 Bethesda Category III thyroid nodules a sensitivity of 90.9%, 
specificity of 92.1%, PPV of 76.9%, and NPV of 97.2% was seen. [41].  Using a comprehensive NGS 
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panel such as ThyroSeq 2 identification of RAS or a RAS-like mutation implies a high probability 
(~80%) of either a low-risk cancer or NIFTP for which surgery can often be limited to thyroid 
lobectomy. Test positivity for an isolated BRAF V600E or other BRAF V600E-like mutation implies a 
very high (>99%) probability of cancer, expected to be of intermediate risk for disease recurrence. 
These patients may undergo total thyroidectomy or lobectomy, depending on the clinical situation. 
ThyroSeq 2 positivity for multiple mutations or high-risk mutations such as TERT is virtually 
diagnostic of cancer and increased risk of disease recurrence and possibly cancer-related mortality 
so these patients can benefit from total thyroidectomy. 
Practical applications 
A recently published Template for Reporting Results of Biomarker Testing for Patients with Suspected 
Thyroid Carcinoma produced by the College of American Pathologists gives a series of practical 
explanatory notes on the clinical significance of identified mutations of BRAF V600E, RAS, PIK3A, 
AKT1, TP53, CTNNB1, RET, ALK, NTRK1, NTRK3 and PPARG. [42] 5 to 10% of thyroid cancers do not 
appear to have a specifically identifiable driver gene mutation that can be identified using existing 
molecular techniques and there is an overlap in the mutational profiles of benign and malignant 
thyroid lesions particularly a problem with follicular adenoma and follicular carcinoma as both 
benign and malignant thyroid lesions may show identical point RAS gene mutations. A task force of 
the European Thyroid Association (ETA) has also just recently produced guidelines for thyroid nodule 
molecular fine needle aspiration diagnostics. [43]. The ETA guidelines conclude that molecular tests 
may help clinicians to drive patient care and surgical decision making if analysis is performed in 
specialised laboratories, requiring standardisation of performance characteristics, appropriate 
calibration, and analytical validation for clinical interpretation. 
 
BRAF V600E Mutation 
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(i)Diagnosis of papillary carcinoma in higher risk FNA: In patients with Bethesda Category V/Thy4 
FNA’s  molecular testing of the sample for BRAF V600E mutation is useful as approximately 50% of 
the specimens will show evidence of a BRAF V600E mutation and therefore management can be 
escalated to that of a category VI/Thy5 lesion malignant lesion. 
(ii)As a test of exclusion for NIFTP tumours: As NIFTP tumours rarely show evidence of BRAF V600E 
mutations the presence of a BRAF V600E mutation virtually excludes a diagnosis of NIFTP 
(iii)Confirmation of the diagnosis of papillary thyroid carcinoma. This is useful in paucicellular FNA’s 
or cell block samples or supernatant samples from the thyroid as BRAF V600E mutation is almost 
100% specific for a diagnosis of papillary thyroid carcinoma. This is most helpful if the patient is 
known to have pre-existing BRAF V600E mutation positive thyroid carcinoma and the sample is a 
suspected recurrent or metastatic thyroid carcinoma. 
(iv) Morphological Phenotyping. BRAF V600E mutated thyroid carcinoma cells have a fairly 
characteristic morphology in many cases with pink cytoplasm evident in both cytological and 
histological preparations. This effect was noted initially in histological specimens by the presence of 
moderate to abundant eosinophilic cytoplasm in tumour cells that were polygonal or somewhat tall 
but did not quite meet the criteria for tall cell variant so called  ‘plump pink cells’. [44] Plump pink 
cells are extremely common in BRAF V600E-mutated tumours and this has now been confirmed in 
cytological preparations with cytologically plump cells with sickle shaped nuclei in the majority of 
cases. [45, 46]  
7 Gene Test 
(v) The reported results of these tests in the literature are conflicting as the results range from 18-
100% sensitivity, 86-100% specificity, 56-100% negative predictive value and 19-100% positive 
predictive value depending to the clinical setting, that is the risk of malignancy of the individual FNA 
being submitted for molecular testing and the institution concerned.  The ETA guidance concludes 
12 
 
that for cytologically indeterminate nodules, BRAF, RET/PTC, PAX8/PPARG and RAS mutational 
analysis should be considered although the significance of RAS mutations needs to be clarified. [43] 
Afirma 
(vi) As a ‘rule-out’ test of exclusion for malignancy Afirma has been deployed in North America with 
high success as a test of exclusion for indeterminate;  Bethesda category III and IV nodules.  
Comprehensive NGS Panel.  
(vii) Thyroseq v2 can be used as a highly effective ‘rule-in’ and ‘rule-out’ test for malignancy. 
Tumour prognostication  
(viii) Thyroid FNA can be used as a prognostic indicator if specific gene mutations or phenotypic 
alterations can be identified. While BRAF V600E mutation alone may confer slightly adverse 
prognosis in any given case, the adverse effect of this mutation alone is small  although recent 
evidence indicates that a combination(s) of BRAF V600E mutation with other gene mutations e.g. 
BRAF V600E and TERT promoter mutation, or coexistent mutations of BRAF V600E and TP53, PIK3CA, 
AKT1 or ALK fusions convey significant adverse prognosis all of which can be identified using 
multigene next-generation sequencing panels.  
Conclusion 
Molecular methods have become important as diagnostic and developmental tools in thyroid 
disease and in the understanding of the pathogenesis of thyroid cancer, in diagnosis, prognosis, and 
treatment. Many of these methods can be used preoperatively on small samples of DNA or RNA or 
micro-RNAs from thyroid FNA aspirates if resources are available although given the complexities of 
testing and test validation most of the methods described are most suited to a specialised referral 
laboratory setting.  
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Figure Legends 
Table 1 
Mutational profiles seen in thyroid tumours. Note that the profile of follicular adenoma and NIFTP 
overlaps considerably with encapsulated follicular variant of papillary carcinoma and follicular 
carcinoma (follicular-like tumours) whereas classical type papillary carcinoma shows a mutational 
profile with BRAF V600E mutation 
Figure 1 
Illustration re-drawn from the 2015 American Thyroid Association Management Guidelines for Adult 
Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma; Risk of Structural Disease 
Recurrence in Patients without Structural Identifiable Disease after Initial Therapy showing how 
molecular profiling; BRAF V600E mutation & TERT promoter mutations can be used to prognostically 
profile thyroid nodules 
Figure 2  
Putative molecular pathogenic pathway for thyroid tumours. Classical type papillary carcinoma is 
typically BRAF V600E driven, whereas follicular adenoma, follicular thyroid carcinoma and NIFTP are 
RAS driven lesions 
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